Photosensitizer
ApprovedSmall molecule
Photosensitizer is one of 25 small molecule programs targeting Bile Duct Cancer. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Bile Duct Cancer
#DrugCompanyPhaseTrials
1Stivarga
BayerApproved
Photofrin
PPinnacle Biologics Inc.
Approved
Ixempra
RR-Pharm
Approved
Gemzar
Johnson & JohnsonPhase 2
Keytruda
Merck & Co.Phase 2
Abraxane
Bristol-Myers SquibbPhase 2
Lynparza
AstraZenecaPhase 2
Koselugo
AstraZenecaPhase 2
Imfinzi
AstraZenecaPhase 2
Taxol
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bile Duct Cancer1 trial
Cardiac1 trial
Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer
Unknown status·TThe First Affiliated Hospital of Henan University of Science and Technology·Phase 3·NCT02628665·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Photosensitizer. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Leipzig